Please use this identifier to cite or link to this item:
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
- IOC - Artigos de Periódicos [12821]
Metadata
Show full item record
INTRADERMAL IMMUNIZATION OF SARS-COV-2 ORIGINAL STRAIN TRIMERIC SPIKE PROTEIN ASSOCIATED TO CPG AND ADDAS03 ADJUVANTS, BUT NOT MPL, PROVIDE STRONG HUMORAL AND CELLULAR RESPONSE IN MICE
Alúmen
AddaS03
CpG
MPL
Adjuvante
Via intradérmica
Via intramuscular
Proteína de pico
Vacina
AddaS03
CpG
MPL
Adjuvants
Intradermal route
Intramuscular route
Spike protein
Vaccine
SARS-CoV-2
Author
Affilliation
Abstract
Despite the intramuscular route being themost used vaccination strategy against SARS-CoV-2,
the intradermal route has been studied around the globe as a strong candidate for immunization
against SARS-CoV-2. Adjuvants have shown to be essential vaccine components that are capable of
driving robust immune responses and increasing the vaccination efficacy. In this work, our group
aimed to develop a vaccination strategy for SARS-CoV-2 using a trimeric spike protein, by testing the
best route with formulations containing the adjuvants AddaS03, CpG, MPL, Alum, or a combination
of two of them. Our results showed that formulations that were made with AddaS03 or CpG alone or
AddaS03 combined with CpG were able to induce high levels of IgG, IgG1, and IgG2a; high titers of
neutralizing antibodies against SARS-CoV-2 original strain; and also induced high hypersensitivity
during the challenge with Spike protein and a high level of IFN-
producing CD4+ T-cells in mice.
Altogether, those data indicate that AddaS03, CpG, or both combined may be used as adjuvants in
vaccines for COVID-19.
Keywords in Portuguese
SARS-CoV-2Alúmen
AddaS03
CpG
MPL
Adjuvante
Via intradérmica
Via intramuscular
Proteína de pico
Vacina
Keywords
AlumAddaS03
CpG
MPL
Adjuvants
Intradermal route
Intramuscular route
Spike protein
Vaccine
SARS-CoV-2
Share